Aura’s CEO Describes the Challenges of Ocular Melanoma


Elisabet “Eli” de los Pinos founded Aura Biosciences in 2009 to chase down innovative treatments for cancer. AURA, which made its first presentation at OIS in 2015, is reporting promising progress with AU-O11, a drug delivery technology that can deliver cancer-killing drugs to the surface of the eye.

Speaking With:

Elisabet-de-los-Pinos

Elisabet de los Pinos, PhD

Elisabet de los Pinos is the Founder and CEO of Aura Biosciences. Eli founded Aura with a vision to transform cancer treatment by developing a novel class of targeted cancer therapy using viral-like particles (VLPs) to deliver drugs selectively to cancer cells, while leaving surrounding tissue unharmed.

View Full Profile